Optimizing combination therapy for type 2 diabetes in adolescents and adults: A case-based approach

Journal of Family Practice

Volumn 53, Issue 10, 2004, Pages 815-822

  Elasy, Tom A ^a,d   Levy, Philip ^{b,d,e,f,g,h,i,j,k}   Davis, Stephen N ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Aventis Pharmaceuticals   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Health Economics and Outcomes Research Head   (Switzerland)

^g NOVO NORDISK INC   (United States)

^h PFIZER INC   (United States)

ⁱ Takeda Pharmaceuticals America Inc   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GLYCEMIC INDEX; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; LABORATORY TEST; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; REVIEW; RISK FACTOR; SCREENING; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION;

EID: 5344255303     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
3. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
4. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
5. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2003. 1-14. 2003.
6. Aye T, Levitsky LL. Type 2 diabetes: an epidemic disease in childhood. Curr Opin Pediatr. 2003;15:411-415.
7. Rosenbloom AL. Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatr Drugs. 2002;4:209-221.
8. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-2850.
9. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
10. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214-222.
11. Leong KS, Wilding JP. Obesity and diabetes. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13:221-237.
12. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A. 1998;95:2498-2502.
13. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
14. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157:821-827.
15. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802-810.
16. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000;23:381-389.
17. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136:664-672.
18. Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs. 1999;58(suppl 1):41-46.
19. Hathout EH, Thomas W, El Shahawy M, Nahab F, Mace JW. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics. 2001;107:E102.
20. ADA. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-S35.
21. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract. 2002;8(suppl 1):40-82.
22. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89-94.
23. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest. 2000;30(suppl 2):3-11.
24. Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31:671-676.
25. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
26. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;136:449-452.
27. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;137:857.
28. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 2001;135:306.
29. Dhawan M, Agrawal R, Ravi J, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol. 2002;34:582-584.
30. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-121.
31. Al Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000;132:121-124.
32. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care. 1995;18:817-824.
33. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952-959.
34. Hirsch IB. Treatment of patients with severe insulin deficiency; what we have learned over the past 2 years. Am J Med. 2004;116(suppl 3A):17S-22S.
35. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20:292-298.
36. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66:1655-1662.
37. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
38. Dailey GE, III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116:223-229.
39. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230-235.
40. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications. 2003;17:211-217.
41. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care. 2003;26:1685-1690.
42. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003;26:2063-2068.
43. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003;26:2238-2243.
44. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40-47.
45. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
46. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.
47. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2050-2055.
48. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
49. Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61:13-19.
50. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17:467-473.
51. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res. 1996;28:426-429.
52. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163:1306-1316.
53. Shaw JE, Hodge AM, de Court, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050-1054.
54. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care. 2001;24:1397-1402.
55. Decode Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
56. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:1607-1611.
57. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18:S42-S49.
58. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
59. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications. 2003;17:179-185.